Exchange: NASDAQ·Updated 07:50 PM EST

KARD News

News
all
press releases
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
Kardigan, Inc. (Nasdaq: KARD), a precision cardiovascular company, today announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS). The Company also shared insights from a pre-planned analysis of the trials baseline data, as well as new...
Business Wire
Kardigan Completes Enrollment in Phase 2b KATALYST-AV Trial and Announces New Evidence Supporting Patient Selection and Endpoints for the Evaluation of Ataciguat in Aortic Stenosis
Kardigan, Inc. (Nasdaq: KARD), a precision cardiovascular company, today announced enrollment completion in the Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis (AS). The Company also shared insights from a pre-planned analysis of the trials baseline data, as well as new...
Business Wire
More News
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
Analysts initiated bullish coverage on Rubrik, Kardigan, MSG Rangers and Ormat Technologies, with price targets of $155, $50, $257 and $123.read more...
Benzinga
Kardigan Announces Appointment of Kristin Reinke to its Board of Directors
Kardigan, Inc. (Nasdaq: KARD) (Kardigan), a precision cardiovascular company, announced today the appointment of Kristin Reinke to its Board of Directors, where she will serve as chair of the Audit Committee. As part of the Boards public company evolution, Doug Giordano will be stepping down from...
Business Wire
Kardigan to Present at Two September Investor Conferences
Kardigan, Inc. (Nasdaq: KARD) (Kardigan or the Company), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, will participate at the following conferences in September.2026 Cantor Global Healthcare...
Business Wire
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardigan, Inc. (Nasdaq: KARD) (Kardigan or the Company), a clinical-stage precision therapeutics company developing medicines that target the root causes of cardiovascular diseases with no approved treatments, today reported financial results from the second quarter ended June 30, 2026, and...
Business Wire
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kardigan, Inc. (Nasdaq: KARD) (Kardigan), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the closing of its initial public offering of an aggregate 28,750,000...
Business Wire
Kardigan Announces Pricing of Upsized Initial Public Offering
Kardigan, Inc. (Nasdaq: KARD) (Kardigan), a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist, today announced the pricing of its initial public offering of 25,000,000 shares of common...
Business Wire

Advertisement|Remove ads.